Recombinant human growth hormone treatment in children under 2 years of age
Record ID 32013000548
English
Authors' recommendations:
Recombinant human growth hormone (rhGH) is used to treat a variety of childhood diseases affecting growth, including children with growth hormone insufficiency/deficiency, children born small for gestational age, idiopathic short stature, chronic renal insufficiency/failure, Turner syndrome, Prader-Willi syndrome, Noonan syndrome, and short stature homeobox-containing gene deficiency (SHOX-D). The primary goals of growth hormone therapy for children with rhGH are the normalization of height and other growth parameters, such as weight and body composition, during childhood, and attainment of normal adult height.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=2349
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Child, Preschool
- Recombinant Proteins
- Growth Disorders
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2013 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.